Component and method for treating viral disease
AssigneeHonz Pharmaceutical Co., Ltd.
InventorsAltmeyer Ralf, Peijun Ren
Life of this patent
Estimating the term…
Abstract
A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof.
Claims14
A method for alleviating or treating hand foot and mouth disease, comprising:
- administering to a subject in need thereof a composition comprising a P2X receptor antagonist, wherein the P2X receptor antagonist is selected from the group consisting of:
- PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, and a pharmaceutically acceptable salt thereof, wherein a total daily dose of the P2X receptor antagonist is at 50-200 mg/kg body weight.
A method for inhibiting infection by a positive-sense single-stranded RNA picornavirus that causes hand foot and mouth disease, comprising:
- administering to a subject in need thereof an effective amount of a P2X receptor antagonist, wherein the P2X receptor antagonist is selected from the group consisting of:
- PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNT-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, and a pharmaceutically acceptable salt thereof, wherein a total daily dose of the P2X receptor antagonist is at 50-200 mg/kg body weight.
Dependencies are inferred from the claim text.